On August 12, 2019, Shanghai Miran signed a contract with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., the core subsidiary of Huadong Medicine, for the automatic unpacking, weighing and dispensing production line of materials. The production line covers automatic unpacking, crushing and screening, automatic weighing and dispensing. The production line is highly integrated with the pre-treatment process of oral solid preparations, realizing the intellectualization and sealing of material processing. It is another milestone in our second entrepreneurship and transformation to intelligent pharmaceutical equipment (automatic unpacking, crushing and screening system of materials (including online sterilization), automatic weighing and dispensing system of materials, vertical material transfer system, vacuum material transfer system, high-density material transfer system, etc.).
Since 2014, Shanghai Miran has maintained long-term cooperation with Huadong Medicine. Shanghai Miran has witnessed the rapid development of Huadong Medicine. Shanghai Miran has also grown with Huadong Medicine. Thank Huadong Medicine for its trust and support as always.
Huadong Medicine is the first echelon enterprise in China's pharmaceutical industry. Its core wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is a domestic professional and leading R&D and production enterprise of diabetes and organ transplantation drugs, a leading domestic prescription drug enterprise in Zhejiang Province, a national high-tech enterprise, a national innovative enterprise, a national intellectual property demonstration enterprise, a national intellectual property advantage enterprise and one of the top 100 technological innovation capabilities in Zhejiang Province. Huadong Medicine business covers all districts and counties in Zhejiang Province, ranking among the top ten pharmaceutical business enterprises in China for consecutive years, and its pharmaceutical business scale and market share are in the leading position in Zhejiang Province. In 2018, East China Pharmaceutical continued to win a number of honors and awards in China with excellent performance and good governance, and won the "best board of directors award in the investor relations selection of China's main board listed companies" at the ninth Tianma awards. The top 100 listed companies on China's main board selected by the securities times, the golden bull award selected by the China Securities News, and the annual excellent board of directors of China's Listed Companies in 2018. At the 10th China Pharmaceutical entrepreneur and scientist investor conference, East China Pharmaceutical was selected as "top 10 R&D and innovation of China's pharmaceutical listed companies in 2018", "top 10 listed companies with the most investment value in 2018", "Social Responsibility Award for sustainable development". East China Pharmaceutical was once again listed in the fortune China 500 in 2018, ranking 263, and was listed on the list.Forbes' top 50 best listed companies in Asia in 2018. Chairman Li bangliang also won such heavyweight awards as "meritorious figures in the pharmaceutical industry in commemoration of the 40 years of reform and opening up" and "2018 global Zhejiang merchants Gold Award".
